Metindol retard, 75 mg 50 pcs
€12.65 €11.07
Methindol retard has anti-inflammatory, analgesic, antipyretic, desensitizing effect.
Blocks cyclooxygenase in arachidonic acid cascade, inhibits GH biosynthesis.
Indications
Active ingredient
Composition
Active ingredient:
Indomethacin 75 mg.
Auxiliary substances:
microcrystalline cellulose,
potato starch,
Methacrylic acid copolymer,
Talc,
Magnesium stearate.
How to take, the dosage
Metindol retard is taken orally.
In acute conditions, at first 1 tablet 2 times a day for 5-10 days, then 1 tablet once a day (in the evening) for 5-7 days; in chronic conditions, 1 tablet once a day.
Interaction
Enhances plasma concentrations of digoxin, methotrexate and lithium drugs, which may increase their toxicity.
Ethanol, colchicine, GCS and corticotropin increase the risk of GI bleeding.
It increases hypoglycemic effect of insulin and oral hypoglycemic drugs; it increases the effect of indirect anticoagulants, antiaggregants, thrombolytics (alteplase, streptokinase and urokinase) – the risk of bleeding.
Decreases the effect of diuretics; with potassium-saving diuretics the risk of hyperkalemia increases; decreases the effectiveness of uricosuric and hypotensive drugs (including beta-adrenoblockers); increases the side effects of glucocorticosteroids, acetylsalicylic acid, estrogen, etc. NSAIDS.
Cyclosporine and gold drugs increase nephrotoxicity (probably due to inhibition of prostaglandin synthesis in kidneys).
Cefamandol , cefaperazone, cefotetan, valproic acid, plikamycin increase the incidence of hypoprothrombinemia and the risk of bleeding.
Antacids and colestyramine reduce absorption of indomethacin.
Accelerates zidovudine toxicity (due to inhibition of metabolism); in infants, increases the risk of toxic effects of aminoglycosides (because it reduces renal clearance and increases blood concentrations).
Concomitant use with serotonin reuptake inhibitors increases the risk of GI bleeding.
Myelotoxic drugs increase manifestations of hematotoxicity of the drug.
The combined use with paracetamol increases the risk of nephrotoxic effects.
Special Instructions
With caution prescribe the drug Metindol in liver and kidney diseases, diseases of the gastrointestinal tract, arterial hypertension, heart failure, immediately after major surgical interventions.
When treating with the drug Metindol systematic monitoring of liver and kidney function and peripheral blood picture is required.
Methindol should be used with caution in patients with epilepsy, mental disorders, visual and hearing impairment.
Reduces the diuretic effect of diuretics and the effect of beta-blockers.
Contraindications
Side effects
Overdose
Symptoms: nausea, vomiting, severe headache, dizziness, memory problems and disorientation. In more severe cases paresthesias, numbness of extremities and seizures are observed.
Treatment: is rapid elimination of the drug from the body and application of appropriate symptomatic drugs. Indomethacin cannot be eliminated from the body by hemodialysis.
Similarities
Weight | 0.017 kg |
---|---|
Shelf life | 5 years |
Conditions of storage | In a dry, light-protected place at 15-25 °C |
Manufacturer | ICN Polfa Rzeszow S.A., Poland |
Medication form | slow-release tablets |
Brand | ICN Polfa Rzeszow S.A. |
Other forms…
Related products
Buy Metindol retard, 75 mg 50 pcs with delivery to USA, UK, Europe and over 120 other countries.